On this page
⚠ Educational content only Not medical or genetic advice. Speak with a healthcare provider or genetic counsellor before acting on anything here.
IEM

Cerebral creatine deficiency (AGAT)

This condition primarily affects the brain and muscles, leading to developmental delays, intellectual disability, and movement problems. It is a recessively inherited disorder, typically presenting in early childhood.

Autosomal recessive IEM OMIM:612718
Rare
Prevalence
Population estimate
25%
Inheritance
Autosomal recessive - if both parents are carriers, each child has a 25% chance of being affected; a carrier passes the variant on 50% of the time
1
Associated genes
GATM

Available at Jeen Health

Clinical tests that include this

Overview

Cerebral creatine deficiency (AGAT), sometimes referred to as L-Arginine:glycine amidinotransferase (AGAT) deficiency, is a rare genetic disorder that impacts the body's ability to produce creatine [PMID:33675043]. Creatine is a molecule crucial for energy storage and transfer, especially in tissues with high energy demands, such as the brain and muscles. When there isn't enough creatine, these tissues cannot function correctly. This condition is one of several disorders affecting creatine metabolism. While extremely rare, understanding its underlying cause is important for diagnosis and management [PMID:20301704].

Symptoms & clinical features

Individuals with cerebral creatine deficiency (AGAT) typically experience a range of neurological symptoms. These symptoms often become noticeable during infancy or early childhood. Common signs include developmental delay, meaning children reach milestones like walking or talking later than expected. Intellectual disability is frequently observed, varying in severity amongst affected individuals. Movement problems, such as muscle weakness (hypotonia) and difficulties with coordination (ataxia), can also be present. In some cases, individuals may experience seizures. The specific symptoms and their severity can differ between affected people [PMID:33675043].

Video: Genetics 101

Affected organs

The primary organs affected by cerebral creatine deficiency (AGAT) are the brain and muscles. Creatine is essential for the rapid energy supply in these tissues. A lack of creatine in the brain leads to the neurological symptoms such as developmental delay, intellectual disability, seizures, and movement difficulties. Muscles, which also rely heavily on creatine for energy, may exhibit weakness and reduced tone. Other body systems are generally less directly impacted, though the long-term effects on overall well-being can be significant due to the neurological compromise.

Multiple body systems
Multiple body systems
Systemic involvement
Cellular impact
Cellular impact
Mechanism at cellular level

Risks & severity

Cerebral creatine deficiency (AGAT) is considered a rare disorder, with exact prevalence not well established. The condition typically manifests in infancy or early childhood, with symptoms often becoming apparent in the first few years of life. The severity of intellectual disability and neurological symptoms can vary. Without appropriate management, the condition can significantly impact an individual's development and quality of life. Research suggests early diagnosis and potential interventions could positively influence the severity of some symptoms [PMID:20301704].

Genetic causes

Cerebral creatine deficiency (AGAT) is caused by genetic changes in the GATM gene. This gene provides instructions for making an enzyme called glycine amidinotransferase. This enzyme carries out the very first step in the body's process of naturally producing creatine. When there are pathogenic variants in the GATM gene, the enzyme cannot function properly, or is not produced in sufficient amounts. This leads to a reduced ability to synthesise creatine, resulting in the deficiency seen in the brain and muscles. Individuals inherit two copies of the GATM gene, and both copies must carry a pathogenic change for the condition to develop.

  • GATM
    glycine amidinotransferase
    The GATM gene encodes an enzyme crucial for the initial step in creatine biosynthesis, a compound vital for cellular energy storage and utilisation.

Inheritance pattern

Cerebral creatine deficiency (AGAT) has an autosomal recessive inheritance pattern. This means that a child must inherit two altered copies of the GATM gene - one from each parent - to be affected by the condition. Individuals who have one altered GATM gene copy and one functional copy are known as carriers. Carriers typically do not show symptoms of the condition themselves but can pass on the altered gene to their children. If both parents are carriers, there is a 25% chance with each pregnancy that their child will inherit two altered gene copies and develop the condition.

♀ Carrier parent 1 altered copy ♂ Carrier parent 1 altered copy Affected Carrier Carrier Unaffected Affected Carrier Unaffected Circles = females · Squares = males

When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.

Diagnosis & testing

Diagnosis of cerebral creatine deficiency (AGAT) often begins when clinical symptoms suggest a metabolic disorder affecting neurological development. Initial investigations may include brain MRI scans, which can show characteristic findings, and magnetic resonance spectroscopy (MRS), which can measure very low or absent creatine levels in the brain. Biochemical tests, such as analysing creatine and guanidinoacetate (GAA) levels in urine, blood, or cerebrospinal fluid, are also crucial for diagnosis. A definitive diagnosis is confirmed through genetic testing (R-code R148 Neurometabolic disorders) to identify pathogenic variants in the GATM gene [PMID:33675043]. Referral to a clinical genetics service via an NHS Genomic Medicine Centre is the typical pathway for genetic testing.

Management & lifestyle

Management for cerebral creatine deficiency (AGAT) focuses on supplementing oral creatine to bypass the metabolic block. Early intervention is generally considered beneficial for potentially improving neurological outcomes, though the response can vary among individuals. Treatment may also include managing specific symptoms, such as anti-epileptic medications for seizures or physical and occupational therapy for developmental delays and movement difficulties. Regular follow-up with a specialist paediatrician, neurologist, and metabolic team within the NHS is important to monitor progress and adjust treatment as needed. Genetic counsellors can provide essential support and information to families regarding the condition and inheritance.

UK care pathway

In the UK, suspected cases of cerebral creatine deficiency (AGAT) are typically referred through the NHS Genomic Medicine Service. A clinician, often a paediatrician or neurologist, would make a referral to a regional clinical genetics service. Genetic testing for this condition is available through the NHS, falling under R-code R148 for neurometabolic disorders. Once a diagnosis is confirmed, individuals and their families often have access to a genetic counsellor who can provide detailed information, discuss inheritance patterns, and offer support.

Frequently asked questions

What is creatine and why is it important?

Creatine is a natural compound that plays a vital role in providing energy to cells, especially in tissues with high energy demands like the brain and muscles. It acts like an energy reserve, helping these tissues to function properly.

How is cerebral creatine deficiency (AGAT) inherited?

This condition is inherited in an autosomal recessive pattern. This means a child needs to inherit two altered copies of the GATM gene, one from each parent, to develop the condition. Parents who carry one altered copy are typically healthy.

Can diet help manage cerebral creatine deficiency (AGAT)?

While the condition affects metabolism, management typically involves oral creatine supplementation rather than strict dietary modifications. This helps to bypass the body's inability to produce creatine effectively.

Is there a cure for cerebral creatine deficiency (AGAT)?

Currently, there is no cure for cerebral creatine deficiency (AGAT). However, early and consistent oral creatine supplementation can significantly improve or stabilise some symptoms, particularly neurological outcomes.

What kind of specialist doctors manage this condition in the UK?

In the UK, individuals with cerebral creatine deficiency (AGAT) are typically managed by a team of specialists, including paediatricians, neurologists, metabolic doctors, and clinical geneticists, often in conjunction with genetic counsellors.

Educational content. This page is not medical or genetic advice, is not individually reviewed by a clinician for each reader, and should not replace a consultation with a qualified healthcare professional or genetic counsellor.